



## Curriculum Vitae

Personal information **Merja Viikki**

### Work experience

---

Employer: Fimea

Start date: 082024

End date:

Position: Clinical assessor, head of section.

Activities: Clinical medication studies

Country: Finland

Employer: Tampere University

Start date: 072019

End date: 082024

Position: Professor (Psychiatry) (50 %)

Activities:

Country: Finland

Employer: Seinäjoki Central Hospital

Start date: 072019

End date: 082024

Position: Consulting Psychiatrist /Clinical instructor) (50 %)

Activities:

Country: Finland

Employer: Tampere University

Start date: 012019

End date: 072019

Position: Clinical Lecturer (Psychiatry)

Activities:

Country: Finland

Employer: University of Tampere

Start date: 082018

End date: 122018

Position: Professor (Psychiatry)

Activities:

Country: Finland

Employer: University of Tampere

Start date: 102007

End date: 072018

Position: Clinical Lecturer (Psychiatry)

Activities:

Country: Finland

Employer: Tampere Mental Center

Start date: 102007

End date: 052019

Position: Consulting Psychiatrist (13 h/week)

Activities:

Country: Finland

Employer: Tampere University Hospital

Start date: 082007

End date: 092007

Position: Resident in Psychiatry (30 h/week)

Activities:

Country: Finland

Employer: Nokia Mental Center

Start date: 062006

End date: 072007

Position: Resident in Psychiatry (30 h/week)

Activities:

Country: Finland

Employer: Tampere Mental Center

Start date: 062004

End date: 052006

Position: Resident in Psychiatry

Activities:

Country: Finland

Employer: Tampere University Hospital

Start date: 082003

End date: 052004

Position: Post-doctoral researcher in the Department of Psychiatry (20 h /week)

Activities:

Country: Finland

Employer: Tampere Mental Center

Start date: 012002

End date: 072003

Position: Resident in Psychiatry

Activities:

Country: Finland

Employer: Kanta-Häme Central Hospital

Start date: 012001

End date: 122001

Position: Resident in Psychiatry

Activities:

Country: Finland

Employer: Finnish Cancer Registry

Start date: 022000

End date: 122000

Position: Post-doctoral researcher

Activities:

Country: Finland

Employer: Tampere Mental Center

Start date: 012000

End date: 012000

Position: Resident in Psychiatry

Activities:

Country: Finland

Employer: Kanta-Häme Central Hospital

Start date: 101999

End date: 121999

Position: Resident in Psychiatry

Activities:

Country: Finland

Employer: University of Helsinki

Start date: 091997

End date: 101999

Position: PhD researcher

Activities:

Country: Finland

Employer: Health Center of Seinäjoki

Start date: 081997

End date: 081997

Position: Medical doctor in outpatient clinic

Activities:

Country: Finland

Employer: University of Tampere

Start date: 041997

End date: 071997

Position: PhD researcher

Activities:

Country: Finland

Secondary occupation:

2008-17.8.2020 Private Practitioner (Psychiatrist), Psykiatri- ja psykologikeskus Mentoria, Tampere, Finland

## Education and training

---

Subject: University of Tampere

Start date:102007

End date: 062012

Qualification: Title of Docent

Organisation: Psychiatry

Country: Finland

Subject: University of Tampere

Start date:102008

End date:092012

Qualification: Licensed Psychotherapist

Organisation: Cognitive Behavioral Therapy

Country: Finland

Subject: University of Tampere

Start date:012000

End date:032008

Qualification: Specialist in Psychiatry

Organisation:

Country: Finland

Subject: University of Tampere

Start date:041997

End date:111999

Qualification: PhD

Organisation:

Country: Finland

Subject: University of Tampere

Start date:081991

End date:031997

Qualification: Medical Doctor

Organisation:

Country: Finland

Subject: The Finnish Medical Association

Start date:102007

End date:012011

Qualification: Special Competence in Medical Education

Organisation:

Country: Finland

## Additional information

---

### Publications

1. Viikki M, Pukkala E, Hakama M. Bleeding symptoms and subsequent risk of gynecological and other cancers. *Acta Obstet Gynecol Scand.* 1998 May;77(5):564-9.
2. Viikki M, Pukkala E, Hakama M. Risk of endometrial, ovarian, vulvar, and vaginal cancers after a positive cervical cytology followed by negative histology. *Obstet Gynecol.* 1998 Aug;92(2):269-73.
3. Viikki M, Pukkala E, Hakama M. Risk of cervical cancer after a negative Pap smear. *J Med Screen.* 1999;6(2):103-7.
4. Viikki M, Pukkala E, Hakama M. Risk of cervical cancer subsequent to a positive screening cytology: follow-up study in Finland. *Acta Obstet Gynecol Scand.* 2000 Jul;79(7):576-9.
5. Viikki M, Pukkala E, Hakama M. Gynaecological infections as risk determinants of subsequent cervical neoplasia. *Acta Oncol.* 2000;39(1):71-5.
6. Nieminen P, Hakama M, Viikki M, Tarkkanen J, Anttila A. Prospective and randomised public-health trial on neural network-assisted screening for cervical cancer in Finland: results of the first year. *Int J Cancer.* 2003 Jan 20;103(3):422-6.
7. Nieminen P, Vuorma S, Viikki M, Hakama M, Anttila A. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer. *BJOG.* 2004 Aug;111(8):842-8.
8. Illi A, Setälä-Soikkeli E, Kampman O, Viikki M, Nuolivirta T, Poutanen O, Mononen N, Lehtimäki T, Leinonen E. Catechol-O-methyltransferase val108/158met genotype, major depressive disorder and response to SSRI

medication in major depressive disorder. *Psychiatry Res.* 2010 Mar 30;176(1):85-7.

9. Illi A, Setälä-Soikkeli E, Viikki M, Poutanen O, Huhtala H, Mononen N, Lehtimäki T, Leinonen E, Kampman O. 5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. *Neuroreport.* 2009 Aug 5;20(12):1125-8.

10. Anttila S, Viikki M, Huuhka K, Huuhka M, Huhtala H, Rontu R, Lehtimäki T, Leinonen E. TPH2 polymorphisms may modify clinical picture in treatment-resistant depression. *Neurosci Lett.* 2009 Oct 16;464(1):43-6.

11. Viikki M, Kampman O, Illi A, Setälä-Soikkeli E, Anttila S, Huuhka M, Nuolivirta T, Poutanen O, Mononen N, Lehtimäki T, Leinonen E. TPH1 218A/C polymorphisms is associated with major depressive disorder and its treatment response. *Neurosci Lett.* 2010 Jan 1;468(1):80-4.

12. Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Leinonen E. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. *Neurosci Lett.* 2010 Jun 25;477(3):105-8.

13. Illi A, Poutanen O, Setälä-Soikkeli E, Kampman O, Viikki M, Huhtala H, Mononen N, Leinonen E, Lehtimäki T. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD? *Eur Arch Psychiatry Clin Neurosci.* 2010 Jul 17

14. Kampman O, Poutanen O, Illi A, Setälä-Soikkeli E, Viikki M, Nuolivirta T, Leinonen E. Temperament profiles, major depression, and response to treatment with SSRIs in psychiatric outpatients. *Eur Psychiatry.* 2012 May;27(4):245-9.

15. Seppälä JKM, Vanhala M, Kautiainen H, Järvenpää S, Eriksson J, Kampman O, Ovaskainen Y, Viikki M, Koponen H. Beck Depression Inventory (BDI) as a Screening Tool for Depression: A Population-Based Finnish Cohort Study. *Psychiatra Fennica* 2010;41:42-52.

16. Andre K, Kampman O, Setälä-Soikkeli E, Viikki M, Poutanen O, Nuolivirta T, Mononen N, Lehtimäki T, Leinonen E, Illi A. Temperament profiles, 5-HT2A genotype, and response to treatment with SSRIs in major depression. *J Neural Transm.* 2010 Dec;117(12):1431-4.

17. Viikki M, Valtonen HM, Leinonen E. Three cases of hypomania and one of mania during aripiprazole treatment. *Pharmacopsychiatry* 2011 Mar;44(2):78-81.

18. Viikki M, Kampman O, Anttila S, Illi A, Setälä-Soikkeli E, Huuhka M, Mononen N, Lehtimäki T, Leinonen E: P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT. *Neurosci Lett.* 2011 Apr 15;493(3):127-30.
19. Viikki M, Huuhka K, Leinonen E, Illi A, Setälä-Soikkeli E, Anttila S, Huuhka M, Mononen N, Lehtimäki T, Kampman O: Interaction between two HTR2A polymorphisms and gender is associated with treatment response in MDD. *Neurosci Lett.* 2011 Aug 21;501(1):20-4.
20. Seppälä J, Vanhala M, Kautiainen H, Eriksson J, Kampman O, Mäntyselkä P, Oksa H, Ovaskainen Y, Viikki M, Koponen H. Prevalence of metabolic syndrome in subjects with melancholic and non-melancholic depressive symptoms. A Finnish population-based study. *J Affect Disord.* 2012 Feb;136(3):543-9.
21. Seppälä J, Koponen H, Kautiainen H, Eriksson J, Kampman O, Männistö S, Mäntyselkä P, Oksa H, Ovaskainen Y, Viikki M, Vanhala M. Association between folate intake and melancholic depressive symptoms. A Finnish population-based study. *J Affect Disord.* 2012 May;138(3):473-8.
22. Huuhka K, Viikki M, Tammentie T, Tuohimaa K, Björkqvist M, Alanen H-M, Leinonen E, Kampman O. One year follow-up after discontinuing maintenance ECT. *J ECT.* 2012 Dec;28(4):225-8.
23. Illi A, Viikki M, Poutanen O, Setälä-Soikkeli E, Nuolivirta T, Kampman O, Leinonen E, Huhtala H, Mononen N, Lehtimäki T. No support for a role for BDNF gene polymorphisms rs11030101 and rs61888800 in MDD or antidepressant response in patients of Finnish origin. *Psychiatr Genet.* 2013 Feb;23(1):33-5.
24. Viikki M, Järventausta K, Leinonen E, Huuhka M, Mononen N, Lehtimäki T, Kampman O BDNF polymorphism rs11030101 is associated with the efficacy of electroconvulsive therapy in treatment-resistant depression. *Psychiatr Genet.* 2013 Jun;23(3):134-6.
25. Andre K Kampman O, Viikki M, Setälä-Soikkeli E, Illi A, Poutanen O, Mononen N, Leinonen E, Lehtimäki T. TPH1 A218C polymorphism and temperament in major depression. *BMC Psychiatry.* 2013 Apr 18;13:118.

26. Seppälä J, Koponen H, Kautiainen H, Eriksson J, Kampman O, Männistö S, Mäntyselkä P, Oksa H, Ovaskainen Y, Viikki M, Vanhala M. Association between vitamin B12 levels and melancholic depressive symptoms. A Finnish population-based study. *BMC Psychiatry*. 2013 May 24;13(1):145.
27. Viikki M, Kampman O, Seppälä N, Mononen N, Lehtimäki T, Leinonen E. CYP1A2 polymorphism -1545C > T (rs2470890) is associated with increased side effects to clozapine. *BMC Psychiatry*. 2014 Feb 20;14(1):50.
28. Paavonen V, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Leinonen E. A cluster model of temperament as an indicator of antidepressant response and symptom severity in major depression *Psychiatry Investig*. 2014 Jan;11(1):18-23.
29. Kampman O, Viikki M, Huuhka K, Leinonen E. Meta-analysis of anxiety disorders and temperament *Neuropsychobiology*. 2014;69(3):175-86.
30. Seppälä N, Leinonen E, Viikki M, Kampman O. Smoking and weight gain among patients using clozapine. *Nord J Psychiatry*. 2014 Nov;68(8):620-5.
31. Solismaa A, Kampman O, Seppälä N, Viikki M, Mäkelä K-M, Mononen N, Lehtimäki T, Leinonen E: Polymorphism in alpha 2A adrenergic receptor gene associated with sialorrhea in schizophrenia patients on clozapine treatment. *Hum Psychopharmacol*. 2014 Jul;29(4):336-41.
32. Klemettilä J-P, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E: Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. *Psychiatry Res*. 2014 Aug 30;218(3):277-83.
33. Seppälä N, Leinonen E, Viikki M, Solismaa A, Nuolivirta T, Kampman O. Factors associated with subjective side-effects during clozapine treatment. *Nord J Psychiatry*. 2015 Apr;69(3):161-6.
34. Klemettilä JP, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E. Association study of the HTR2C, leptin and adiponectin genes and serum marker analyses in clozapine treated long-term patients with schizophrenia. *Eur Psychiatry*. 2015 Feb;30(2):296-302.
35. Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N,

Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E. SERT and NET polymorphisms, temperament and antidepressant response. *Nord J Psychiatry*. 2015 Oct;69(7):531-8.

---

36. Klemettilä J-P, Kampman O, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E: Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. Resistin as an inflammatory marker in patients with schizophrenia treated with clozapine. *Nordic Journal of Psychiatry*, 71 (2), 89-95

---

37. Klemettilä J-P, Kampman O, Solismaa A, Lyytikäinen LP, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E: Association study of arcuate nucleus neuropeptide Y neuron receptor gene variation and serum NPY levels in clozapine treated patients with schizophrenia. *Eur Psychiatry*. 2017 Feb;40:13-19.

38. Koskinen S, Kampman O, Solismaa A, Lyytikäinen L-P, Seppälä N, Viikki M, Hämäläinen M, Moilanen E, Mononen N, Lehtimäki T, Leinonen E. INSIG2 polymorphism and weight gain, dyslipidemia and serum adiponectin in Finnish patients with schizophrenia treated with clozapine. *Pharmacogenomics*. 2016 Dec;17(18):1987-1997.

39. Kampman O, Viikki M, Leinonen E. Anxiety Disorders and Temperament – an Update Review. *Curr Psychiatry Rep*. 2017 May;19(5):27.

40. Solismaa A, Kampman O, Lyytikäinen L-P, Seppälä N, Viikki M, Mononen N, Lehtimäki T, Leinonen E. Histaminergic gene polymorphisms associated with sedation in clozapine-treated patients. *Eur Neuropsychopharmacol*. 2017 May;27(5):442-449.

41. Andre K, Kampman O, Illi A, Viikki M, Setälä-Soikkeli E, Mononen N, Lehtimäki T, Haraldsson S, Koivisto PA, Leinonen E. BDNF and NRG1 polymorphisms and temperament in selective serotonin reuptake inhibitor-treated patients with major depression. *Acta Neuropsychiatr*. 2018 Jan 9:1-7.

42. Solismaa A, Kampman O, Lyytikäinen L-P, Seppälä N, Viikki M, Mononen N, Lehtimäki T, Leinonen E. Genetic polymorphisms associated with constipation and anticholinergic symptoms in patients receiving clozapine. *J Clin Psychopharmacol*. 2018 Jun;38(3):193-199.

43. Puolakka H, Solismaa A, Lyytikäinen L-P, Viikki M, Seppälä N,

Mononen N, Lehtimäki T, Kampman O. Polymorphisms in ERBB4 and TACR1 associated with dry mouth in clozapine-treated patients. *Acta Neuropsychiatrica* 2024 Apr 18:1-6.

**Projects** Conducted over 20 clinical trials in Major Depressive Disorder, Generalized Anxiety Disorder, Insomnia and ADHD in 2008-2020.

**Memberships**

**Other Relevant Information**